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oloOBJECTIVES The primary objective was to identify well-tolerated doses of cimlanod in patients with acute heart failure
(AHF). Secondary objectives were to identify signals of efficacy, including biomarkers, symptoms, and clinical events.
BACKGROUND Nitroxyl (HNO) donors have vasodilator, inotropic and lusitropic effects. Bristol-Myers Squibb-986231
(cimlanod) is an HNO donor being developed for acute heart failure (AHF).
METHODS This was a phase IIb, double-blind, randomized, placebo-controlled trial of 48-h treatment with cimlanod
compared with placebo in patients with left ventricular ejection fraction #40% hospitalized for AHF. In part I, patients
were randomized in a 1:1 ratio to escalating doses of cimlanod or matching placebo. In part II, patients were randomized in
a 1:1:1 ratio to either of the 2 highest tolerated doses of cimlanod from part I or placebo. The primary endpoint was the
rate of clinically relevant hypotension (systolic blood pressure <90 mm Hg or patients became symptomatic).
RESULTS In part I (n ¼ 100), clinically relevant hypotension was more common with cimlanod than placebo (20% vs.
8%; relative risk [RR]: 2.45; 95% confidence interval [CI]: 0.83 to 14.53). In part II (n ¼ 222), the incidence of clinically
relevant hypotension was 18% for placebo, 21% for cimlanod 6 mg/kg/min (RR: 1.15; 95% CI: 0.58 to 2.43), and 35% for
cimlanod 12 mg/kg/min (RR: 1.9; 95% CI: 1.04 to 3.59). N-terminal pro–B-type natriuretic peptide and bilirubin decreased
during infusion of cimlanod treatment compared with placebo, but these differences did not persist after treatment
discontinuation.
CONCLUSIONS Cimlanod at a dose of 6 mg/kg/min was reasonably well-tolerated compared with placebo. Cimlanod
reduced markers of congestion, but this did not persist beyond the treatment period. (Evaluate the Safety and Efficacy of
48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure [STANDUP AHF]; NCT03016325)
(J Am Coll Cardiol HF 2021;9:146–57) © 2021 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).N 2213-1779 https://doi.org/10.1016/j.jchf.2020.10.012
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147AB BR E V I A T I O N S
AND ACRONYM S
AHF = acute heart failure
CI = confidence interval
HNO = nitroxyl
IV = intravenous
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
RR = relative risk
= systolic blood pressureA ttempts to develop effective new therapies forpatients hospitalized with acute heart failure(AHF) have been unsuccessful, and intrave-
nous (IV) loop diuretic agents remain the mainstay of
management. Current treatment guidelines recom-
mend vasodilators (e.g., nitroglycerin) in patients
with elevated blood pressure (1), although high-
quality data supporting this recommendation are
sparse, and recent studies have called this strategy
into question (2). Although signs and symptoms of
AHF usually improve with treatment, congestion is
often persistent at hospital discharge, contributing to
high rates of recurrent hospitalization and death (3).SEE PAGE 158HNO gas (nitroxyl) is a chemical sibling of nitric
oxide. Although nitric oxide and HNO appear to be
closely related chemically, the physiological effects
and biologic mechanisms of HNO and nitric oxide
action are distinct (4). The biologic effects of HNO are
mediated by direct post-translational modification of
thiol residues in target proteins, including SERCA2a,
phospholamban, the ryanodine receptor, and
myofilament proteins in cardiomyocytes (5–8).
In vitro, HNO increases the efficiency of calcium
cycling and improves myofilament calcium sensi-
tivity, which enhances myocardial contraction and
relaxation (9). HNO also mediates peripheral vasodi-
lation through endothelial soluble guanylate cyclase
(5). HNO does not induce tachyphylaxis in peripheral
vessels, unlike nitric oxide (10).
In large animal models of heart failure, HNO do-
nors directly enhanced myocardial contractility and
relaxation, and reduced pre-load and afterload
without increasing heart rate or myocardial oxygen
consumption (11,12). This combination of physiolog-
ical effects makes HNO pro-drugs potentially
attractive therapeutic candidates in heart failure.
Bristol-Myers Squibb-986231 (cimlanod) is an HNO
donor being developed for AHF. Short-term treat-
ment with cimlanod has caused venous and arteriolar
dilation and may have had inotropic effects inde Paris, Inserm 942-MASCOT, FHU PROMICE, Paris, France; oInstitute
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failure (13). We now report the results of the
STAND-UP AHF (Study Assessing Nitorxyl
Donor Upon Presentation with Acute
Heart Failure) trial, a phase II, randomized,
double-blind, placebo-controlled clinical trial
of cimlanod in patients hospitalized for AHF.
METHODS
STUDY DESIGN. The detailed rationale and
design of this trial was published previously
(NCT03016325) (14). The study was approved by the
relevant institutional review boards/ethics commit-
tee at each study site, and all patients provided
informed consent. Briefly, STAND-UP AHF was an
international, multicenter, randomized, double-
blind, placebo-controlled ascending dose clinical
trial of continuous 48-h IV infusions of cimlanod or
placebo in patients with heart failure with reduced
ejection fractions who were hospitalized with AHF.
Cimlanod or matching placebo was administered in
addition to background therapy. The primary objec-
tive was to evaluate the effects of various doses of
cimlanod compared with placebo on the risk of clin-
ically relevant hypotension (defined as systolic blood
pressure [SBP] <90 mm Hg or symptoms of hypo-
tension). The trial consisted of 2 sequential parts,
each with a unique cohort of patients. In part I, 100
patients were randomized in a 1:1 ratio to escalating
doses of cimlanod (3 mg/kg/min for 4 h, then 6 mg/kg/
min for another 4 h, then 12 mg/kg/min for the
remaining 40 h) or escalating doses of placebo. In part
II of the study, 222 patients were randomized in a 1:1:1
ratio to 1 of the 2 highest tolerated doses of cimlanod
in part 1 (6 and 12 mg/kg/min) or placebo.
To mitigate the risks of hypotension, the study
protocol specified down titration of infusions (50%
decrease) if a patient experienced SBP <95 mm Hg
(confirmed by repeat measurement within 15 min). If
SBP fell to <85 mm Hg or if there were symptoms of
hypotension, the study drug was interrupted for at
SBPof Cardiology, ASST Spedali Civili di Brescia and
Public Health, University of Brescia, Brescia, Italy;
etherlands and Dutch Network for Cardiovascular
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TABLE 1 Baseline Characteristics














Age, yrs 66  12 65  12 67  12 69  11 70  12
Female 17 20 25 28 21
Race, Black 23 22 6 10 6
LVEF, % 26  8 27  7 28  8 27  9 26  7
Hospitalizations for
HF in past year
1.5  1.0 1.4  1.0 0.6  0.8 0.5  1.1 0.7  0.9
Atrial fibrillation 46 49 52 41 46
Diabetes 52 61 47 31 49
MI 44 43 37 30 46
Hypertension 83 88 76 82 79
SBP, mm Hg 126  15 125  16 123  15 122  13 123  16
HR, beats/min 80  16 81  15 82  16 82  16 80  16
NT-proBNP, pg/ml 8,763 (5,700) 8,675 (5,576) 7,423 (5,515) 8,499 (5,810) 8,043 (5,218)
Creatinine, mg/dl 1.5  0.5 1.4  0.5 1.3  0.4 1.2  0.3 1.2  0.4
Time since
presentation, h
11.8  6 11.9  5 19.6  9.9 17.3  7.9 17.1  9.5
Background medications
BB 81 82 85 90 85
RAAS inhibitors
(ACEi/ARB/ARNi)
73 65 80 83 74
Sacubitril/valsartan 13 4 10 6 6
MRA 48 43 68 79 54
Values are mean  SD, %, or mean (median).
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ARNi ¼ angiotensin
receptor-neprilysin inhibitor; BB ¼ beta-blocker; HF ¼ heart failure; HR ¼ heart rate; LVEF¼left ventricular
ejection fraction, MI ¼ myocardial infarction; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼
N-terminal proB-type natriuretic peptide; RAAS ¼ renin-angiotensin-aldosterone system; SBP ¼ systolic blood
pressure.
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148least 1 h and then resumed at 50% of the previous rate
if SBP was 105 mm Hg and symptoms of hypotension
had resolved. After dose reductions, the dose was not
further increased. After a dose decrease, infusions
were permanently discontinued if criteria for dose
reduction or interruption were met again.
PATIENTS. Enrolled patients were hospitalized for
AHF with signs and symptoms of congestion that
required treatment with IV loop diuretics. Patients
were required to have a history of chronic heart fail-
ure with a reduced ejection fraction with a docu-
mented ejection fraction #40% within the previous
18 months. Patients with SBP <105 mm Hg or
>160 mm Hg were ineligible. Patients could not be
receiving IV vasodilators or IV inotropic agents at the
time of randomization, with the exception of IV
nitroglycerin at a stable dose of <100 mg/min with a
SBP of >120 mm Hg. Patients were required to have
increased plasma concentrations of natriuretic pep-
tides (N-terminal pro-B-type natriuretic peptide [NT-
proBNP] $1,600 pg/ml or B-BNP $400 pg/ml [$2,400
pg/ml NT pro-BNP or 600 pg/ml BNP if atrial fibrilla-
tion was present at baseline]). For part I, patients hadto be randomized within 18 h of their initial dose of IV
loop diuretics. This time window for enrollment was
expanded to 48 h for part II.
ENDPOINTS. The primary endpoint was the inci-
dence of clinically relevant hypotension, defined by
either SBP <90 mm Hg (confirmed by repeat mea-
surement) or symptoms of hypotension, which
occurred up to 6 h after the end of study drug infu-
sion. Secondary endpoints were a change in plasma
concentrations of NT-proBNP from baseline at various
time points and a change in patient-reported resting
dyspnea using the area under the curve of an 11-point
numeric rating scale from baseline to 72 h. Other
endpoints of interest included symptoms of dyspnea
and patient global assessment measured by Likert
scales, the incidence of worsening heart failure
(defined as worsening signs or symptoms of heart
failure that required escalation of heart failure ther-
apy) through day 5 or hospital discharge, changes in
renal function, changes in signs and symptoms of
congestion, length of stay, and post-discharge death
or rehospitalization through day 32. Patients were
followed through day 182 for cardiovascular and all-
cause mortality as a safety endpoint.
STATISTICAL ANALYSIS. The primary objective of
the study was to evaluate the effects of various doses
of cimlanod compared with placebo on clinically
relevant hypotension. In part I, approximately 50
patients per group were randomized by 1:1 ratio.
Assuming an incidence rate of clinically relevant hy-
potension in the placebo group ranged from 5% to
10%, the study required >80% power to detect a $3-
fold increase in incidence in the cimlanod group
compared with the placebo group.
At the conclusion of part I, an interim analysis was
conducted to select doses of cimlanod for use in part
II. This analysis was conducted in an unblinded
fashion by the study executive committee and the
study sponsor, with input from the data safety
monitoring committee. The doses selected for part II
(based on the overall totality of the available safety
and efficacy data from part I) were the 2 highest doses
administered in part I, specifically 6 and 12 mg/kg/
min.
For part II, approximately 70 patients per group
were randomized by 1:1:1 ratio into 3 groups. Under
the same assumption of clinically relevant hypoten-
sion incidence in the placebo group, part II would
have at least 80% of power to detect a $2.5-fold in-
crease in incidence for each cimlanod group
compared with placebo without multiplicity adjust-
ment. The relative risk (RR) of clinically relevant hy-
potension between cimlanod and placebo and its
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SBP <90 mm Hg Symptomatic Hypotension
C
Felker, G.M. et al. J Am Coll Cardiol HF. 2021;9(2):146–57.
Incidence of clinically relevant hypotension (primary endpoint) and changes in N-terminal pro–B-type natriuretic peptide (NT-proBNP) after study drug treatment for
(A and B) part I and (C and D) part II. For clinically relevant hypotension, patients having both symptomatic hypotension and systolic blood pressure
(SBP) <90 mm Hg were included in the symptomatic group (orange bars).
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FIGURE 1 Change in BP and Heart Rate
Change in blood pressure (BP) and heart rate during and after study drug infusion for (A and B) part I and (C and D) part II. beats/min ¼ beats per minute; SBP ¼ systolic
blood pressure.
Continued on the next page
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150corresponding 95% confidence intervals (CIs) were
calculated using an exact procedure that inverted the
2-sided test statistics.
RESULTS
PATIENTS AND STUDY TREATMENT. Enrollment of
patients into part I began on April 24, 2017, and the
final patient was enrolled in part II on May 15, 2019. A
total of 322 patients were randomized (100 in part I
and 222 in part II) in 13 countries in North America,Europe, South America (part II only), and Japan (part
II only). Baseline characteristics for both cohorts are
shown in Table 1 and were broadly balanced between
randomized groups. In part I, the mean age was 65
years (vs. 69 years in part II); 19% were women (vs.
25% in part II), the mean left ventricular was similar
in the 2 parts (27%), mean SBP was 125 mm Hg (vs.
123 mm Hg in part II), and median NT-proBNP was
5,686 pg/ml (vs. 5,529 pg/ml in part II). As antici-
pated, because of the expansion of the enrollment
time window from 18 to 48 h, a notable difference
FIGURE 1 Continued
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151between parts I and II was the time from initial pre-
sentation to randomization, which was mean 12 h in
part I versus 18 h in part II.
Background medical therapy for heart failure with
reduced ejection fraction included treatment with
beta-blockers (50% in part I and 86% in part II),
modulators of the renin-angiotensin system (75% in
part I and 79% in part II), and mineralocorticoid re-
ceptor antagonists (50% in part I and 65% in part II).
All patients were treated with IV loop diuretic agents
as required by trial inclusion criteria.
In part I, 83% of patients completed the 48-h infu-
sion of placebo compared with 71%who completed the
infusion of cimlanod. In part II, 87% of patients
completed the 48-h infusion of placebo, 79%completed the infusion of cimlanod 6 mg/kg/min, and
75% completed the infusion of cimlanod 12 mg/kg/min.
OUTCOMES. Blood pressure and heart rate .
Results of the primary endpoint analysis are sum-
marized in the Central Illustration. In part I, clinically
relevant hypotension was more common in patients
randomized to cimlanod than placebo (20% vs. 8%;
RR: 2.45; 95% CI: 0.83 to 14.53; p ¼ 0.10). In most
patients, this endpoint reflected asymptomatic
SBP <90 mm Hg, and the incidence of symptomatic
hypotension was low in both groups (6% in the cim-
lanod group and 2% in the placebo group; RR: 2.94;
95% CI: 0.31 to 75.47; p ¼ 0.30). Changes in heart rate
over time were generally similar between patients
TABLE 2 Secondary and Exploratory Endpoints
Part I
Placebo Cimlanod
Treatment Effect vs. Placebo
(95% CI) p Value
Secondary endpoints
NT-proBNP change, %
change at 48 h
36 50 14.3 (26.28 to 2.32) 0.02*
Dyspnea by NRS,
AUC >72 h
173  17 175  16 2.5 (45.89 to 50.96) 0.90†
Exploratory endpoints
Dyspnea improvement by
Likert scale at 24 h, % with
moderate or marked improvement
69 67 0.98 (0.73 to 1.32) 0.90
Patient global assessment improvement
by Likert scale at 24 h,
% with moderate or marked
improvement
65 69 1.07 (0.80 to 1.47) 0.6‡
Worsening HF through
day 5
4 (8.3) 3 (6.1) 0.73 (0.10 to 3.31) 0.70‡
Daily urine volume at
24 h, ml
2,580 (2,200)  1,672 2,932 (2,391)  1,545 NA 0.10‡
Worsening renal function§
through day 5
25 (52) 25 (51) 0.98 (0.65 to 1.48) 0.90§
Mean change in body weight
from baseline, kg
Day 1 0.8 1.3 0.6 (1.62 to 0.49) 0.30*
Day 2 1.9 1.8 0.2 (1.56 to 1.06) 0.70*
Day 5 2.1 3.5 1.8 (4.01 to 0.49) 0.10*










(95% CI) p Value
Treatment Effect
(Placebo vs. 12)
(95% CI) p Value
Secondary endpoints
NT-proBNP change, %
change at 48 h
23 32 44 9.2 (23.68 to 5.23) 0.20* 20.7 (34.99 to 6.39) 0.005*
Dyspnea by NRS,
AUC >72 h
178  20 201  19 198  19 22.1 (61.70 to 17.55) 0.30† 19.2 (58.18 to 19.82) 0.30†
Exploratory endpoints
Dyspnea improvement by
Likert scale at 24 h, % with
moderate or marked improvement
61 65 60 1.07 (0.82 to 1.41) 0.60‡ 0.99 (0.74 to 1.31) 0.90‡
Patient global assessment improvement
by Likert scale at 24 h,
% with moderate or marked
improvement
61 62 58 1.02 (0.78 to 1.35) 0.90‡ 0.96 (0.72 to 1.29) 0.80‡
Worsening HF through
day 5
5 (7) 0 (0) 4 (6) 0 (0.00 to 0.94) 0.02‡ 0.79 (0.18 to 3.21) 0.70‡








NA 0.30‡ NA 0.20‡
Worsening renal function§
through day 5
29 (41) 40 (56) 25 (35) 1.38 (0.97 to 2.04) 0.06‡ 0.85 (0.54 to 1.32) 0.40‡
Mean change in body weight
from baseline, kg
Day 1 1.4 0.9 1.1 0.7 (0.05 to 1.35) 0.07* 0.4 (0.33 to 1.05) 0.30*
Day 2 2.1 1.6 1.8 0.5 (0.30 to 1.35) 0.20* 0.4 (0.45 to 1.19) 0.40*
Day 5 2.6 3 3.2 0.1 (1.01 to 1.30) 0.80* 0.5 (1.63 to 0.71) 0.50*
Length of stay, median days 6 7 6 NA 0.10‡ NA 0.70‡
Values are n (%), mean  SD, or mean (median)  SD. *F-statistic. †Mixed model. ‡Chi-square test. §Worsening renal function defined as increase from baseline in cystatin C values
by $0.3 mg/l or in serum creatinine by $0.3 mg/dl (27 mmol/l).
AUC ¼ area under the curve; CI ¼ confidence interval; NRS ¼ numerical rating scale; RR ¼ relative risk; other abbreviations as in Table 1.
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153randomized to cimlanod or placebo (Figure 1). Based
on review of these data by the executive committee,
data safety monitoring committee, and study
sponsor, the 2 highest doses (6 and 12 mg/kg/min)
from part I were selected for further study in part II.
In part II, the incidence of clinically relevant hy-
potension was 18% for placebo, 21% for cimlanod
6 mg/kg/min (RR: 1.15; 95% CI: 0.58 to 2.43; p ¼ 0.70),
and 35% for cimlanod 12 mg/kg/min (RR: 1.9; 95% CI:
1.04 to 3.59; p ¼ 0.03). Symptomatic hypotension
occurred in 1% on placebo, 3% on 6 mg/kg/min (RR:
2.0; 95% CI: 0.18 to 54.35; p ¼ 0.60), and 8% on 12 mg/
kg/min (RR: 5.92; 95% CI: 0.91 to 159.72; p ¼ 0.06).
Dose reduction was required in 13% of patients on
placebo, 14% on 6 mg/kg/min (RR: 1.1; 95% CI: 0.47 to
2.85; p ¼ 0.80), and 35% on 12 mg/kg/min (RR: 2.74;
95% CI: 1.34 to 6.89; p ¼ 0.002), whereas dose
discontinuation due to hypotension occurred in 10%
on placebo, 18% on 6 mg/kg/min (RR: 1.86; 95% CI:
0.80 to 5.11; p ¼ 0.10), and 21% on 12 mg/kg/min (RR:
2.1; 95% CI: 0.92 to 5.85; p ¼ 0.07). Compared with
patients randomized to placebo, heart rates were
generally higher over time in patients randomized to
the highest dose (12 mg/kg/min) of cimlanod but
generally lower in patients randomized to the lower
dose (6 mg/kg/min) (Figure 1).
EFFICACY. Although this study was not powered for
efficacy, there were a variety of efficacy signals of
interest as secondary and exploratory endpoints, the
results of which are summarized in Table 2. Changes
in NT-proBNP over time for cimlanod versus placebo
are shown in the Central Illustration. In both parts I
and II, an NT-proBNP decrease during treatment was
greater during the 48 h of active treatment with
cimlanod than that with placebo. In part I, the
decrease in NT-proBNP at 48 h was 36% in the pla-
cebo group and 50% in the cimlanod group. The
proportion of patients who experienced a $30%
decrease in NT-proBNP by 48 h was significantly
greater in patients treated with cimlanod than those
who received the placebo (76% vs. 54%; p ¼ 0.03).
Similarly, in part II, the decrease in NT-proBNP at
48 h was 23% in the placebo group, 32% in the cim-
lanod 6 mg/kg/min group, and 44% in the cimlanod
12 mg/kg/min group. The proportion of patients who
experienced a $30% decrease in NT-proBNP by 48 h
was again significantly greater in patients treated
with cimlanod compared with those who received
placebo: 71% versus 62% versus 47% for cimlanod
12 mg/kg/min, 6 mg/kg/min, and placebo, respectively
(p ¼ 0.06 for 6 mg/kg/min vs. placebo, and p ¼ 0.003for 12 mg/kg/min vs. placebo). Overall, these data
suggested a dose-dependent effect of cimlanod on
plasma concentrations of NT-proBNP. However, in
both parts I and II, these differences in NT-proBNP
waned after the 48-h active treatment period was
completed (Central Illustration).
Symptoms of dyspnea by numerical rating scale
improved in all groups during hospitalization, and
the improvement was generally similar for patients
assigned to either cimlanod or placebo (Figure 2).
Physical examination findings of congestion, urinary
volumes, and changes in body weight were also
generally similar between the study groups in both
parts I and II.
In addition to the NT-proBNP results described
previously, laboratory data were generally consistent
with an unloading effect during cimlanod infusion,
which waned when treatment was stopped (Figure 3).
Serum creatinine increased transiently during cimla-
nod treatment compared with that of placebo, but
this difference did not persist after treatment was
discontinued. Serum bilirubin concentrations mark-
edly decreased during cimlanod infusion compared
with placebo. Cardiac troponin did not differ signifi-
cantly over time between patients randomized to
cimlanod or placebo.
Data on post-discharge events are provided in
Table 3. Because this program was not powered
for clinical outcomes and the numbers of events
were small, we pooled clinical outcomes data from
parts I and II for analysis. Length of stay (from
randomization to hospital discharge) was similar in
both groups (median 6 days in both groups), and
rates of post-discharge events were not different.
The incidence of cardiovascular death or rehospi-
talization at 32 days from randomization was 5.7%
in patients treated with cimlanod and 9.6% in
patients treated with placebo. The incidence of
cardiovascular death at 182 days was 8.3% in
cimlanod-treated patients and 10.1% in those
treated with placebo.
ADVERSE EVENTS. Safety events are summarized in
Table 4. In pooled data (part I and part II combined),
74% of patients randomized to cimlanod had an
adverse event compared with 66% randomized to
placebo. In contrast, serious adverse events weremore
common in patients in the placebo group (29%) versus
those in the cimlanod group (23%). The most common
adverse event leading to drug discontinuation was
hypotension, which was more common in the cimla-
nod group (19%) than in the placebo group (9%).
FIGURE 2 Patient-Reported Dyspnea
Patient reported dyspnea using a 11-point numerical rating scale over 72 h.
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154DISCUSSION
The primary goal of the present study was to identify
a dose or doses of cimlanod that had acceptable rates
of hypotension in the target population (patients with
heart failure with reduced ejection fraction hospital-
ized for AHF) that could be used in future clinical
outcome studies. As anticipated for an IV agent with
vasodilator properties, both the 6 and 12 mg/kg/min
doses of cimlanod were associated with a higher
incidence of clinically significant hypotension than
that of placebo. Although the patient characteristics
and specific definitions of hypotension differed be-
tween the present trial and previous studies of AHF,
the rates of hypotension observed with cimlanod
were generally similar to those seen in other trials of
IV vasodilators in AHF, such as nesiritide (27% in
ASCEND-HF [Acute Study of Clinical Effectiveness of
Nesiritide in Decompensated Heart Failure]) (15),
serelaxin (19% in RELAX-AHF-2 [Relaxin in Acute
Heart Failure-2]) (16), and ularitide (22% in TRUE-
HF [Trial of Ularitide Efficacy and Safety in Acute
Heart Failure]) (17). Rates of hypotension with the
highest studied dose of cimlanod (12 mg/kg/min) were
greater (35%) than that in the other study arms, and asubstantial proportion of patients who received this
dose required dose reduction or discontinuation (35%
and 21%, respectively). This finding suggested that
6 mg/kg/min had a more acceptable safety profile in
the population studied in the present trial. Gradual
up-titration to the highest tolerated dose (as per-
formed in part I) could allow for more individualized
dosing and could also be a viable alternate strategy.
Because of the putative mechanisms of cimlanod
in HF, including vasodilator, inotropic, and lusi-
tropic effects, we hypothesized that treatment with
cimlanod would facilitate more rapid and complete
decongestion, potentially improving the in-hospital
clinical course and decreasing post-discharge
events. We assessed several clinical and laboratory
measures of ventricular unloading. Plasma concen-
trations of NT-proBNP, a biomarker of myocardial
stress, fell during infusion of cimlanod compared
with placebo, but these differences did not persist
beyond the 48-h treatment period. Changes in car-
diac troponin, a marker of myocardial injury, did not
differ between groups. Serum creatinine rose
modestly during cimlanod infusion compared with
placebo. This suggested a decongestive effect similar
to that seen with a high dose versus a low dose
FIGURE 3 Change in Serum Creatinine
Change in (A) serum creatinine and (B) bilirubin after study drug treatment.
TABLE 3 Post-Discharge Clinical Events






Median days alive and
out of hospital
through day 32
24 26 25 25 25
HF hospitalization
or CV death
through day 32, %
4 4 10 7 6
CV death through
day 180, %
6 4 13 14 6
CV ¼ cardiovascular; HF ¼ heart failure.
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155diuretic therapy in the DOSE (Diuretic Optimization
Strategies Evaluation) trial (18). Bilirubin, a marker
of adverse outcomes in AHF (19,20), also transiently
improved with cimlanod compared with placebo.
Collectively, these data suggested a greater reduc-
tion in congestion with cimlanod compared with
placebo. The mechanism of the observed effect on
congestion was not clear from this study, because
we did not find significant differences in urine
output, symptoms, or changes in body weight. The
transient improvements in measures of congestion
during treatment that waned with treatment cessa-
tion were similar to data from other trials of vaso-
dilators in AHF, in particular with serelaxin (21,22)





Patients with an AE 79 (66.4) 142 (74.0)
Deaths 6 (5.0) 8 (4.2)
Patients with serious AEs 34 (28.6) 44 (22.9)
Patients with AEs leading to
discontinuation
12 (10.1) 41 (21.4)
Discontinuation due to hypotension 11 (9.2) 37 (19.3)
Drug-related AEs (including hypotension) 20 (16.8) 76 (39.6)
Values are n (%).
AE ¼ adverse event.
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156and ularitide (17). A key question is whether these
short-term effects on congestion translate into
longer term benefits. In theory, more effective acute
treatment of congestion could improve the in-
hospital course, reduce rates of in-hospital wors-
ening heart failure and other adverse events,
shorten length of stay, and reduce rehospitalizations
for heart failure. However, these hypothesized
longer term benefits have not been confirmed in
trials of short-term infusions of novel vasodilators. A
recent randomized trial of clinically available vaso-
dilators (primarily nitrates and oral hydralazine)
given acutely to patients with AHF also failed to
demonstrate longer term clinical benefits (2). Mea-
sures of clinical status in the hospital (in-patient
worsening heart failure, length of stay) and post-
discharge events (heart failure rehospitalizations
through day 32 and cardiovascular deaths through
day 182) did not differ between cimlanod and pla-
cebo. Other than the expected adverse effect of hy-
potension, cimlanod was generally well tolerated,
with an overall rate of adverse events and serious
adverse events similar to placebo.
STUDY LIMITATIONS. We enrolled patients with a
history of chronic heart failure and a left ventricular
ejection fraction of#40%. Patients with de novo heart
failure or patients with heart failure and preserved
ejection fraction were excluded, which limited our
ability to draw conclusions about these patient groups.
As a phase II study, STAND-UPAHFwas not powered to
draw conclusions about clinical endpoints.
CONCLUSIONS
Treatment with cimlanod (6 mg/kg/min) in patients with
AHF and reduced systolic function improved some pa-
rameters related to congestion at the cost of a modest in-
crease in hypotension rates.We did not identify persistent
effects of cimlanod after the infusion was stopped. Other
ongoing trials are evaluating the effects of cimlanod on
hemodynamics, renal function, and diuresis (A Study ofContinuous Infusions of HNO (Nitroxyl) Donor in Patients
With Heart Failure and Impaired Systolic Function;
NCT03357731 and An Investigational Study of Continuous
8-Hour Intravenous Administrations of Bristol-Myers
Squibb-986231 in Participants With Heart Failure and
Reduced Heart Function Given a Standard Dose of Loop
Diuretic; NCT03730961). Collectively, the results of these
studies will inform the continued development of cimla-
nod for patients with heart failure.
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